A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2013
At a glance
- Drugs Entolimod (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 10 Dec 2013 Planned initiation date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 10 Dec 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.